Affibody and Inmagene autoimmune partnership completes regulatory milestone
Affibody and Inmagene Biopharmaceuticals report that the US FDA has cleared the interleukin-17 (IL-17) blocker, izokibep, to proceed to phase 2 clinical development in non-infectious intermediate, posterior, and pan-uveitis.
Uveitis is an orphan disease with significant unmet medical need. It is an inflammation of the uveal tract but can also include the inflammation of nearby tissues, such as the retina, the optic nerve, and the vitreous humor. It is one of the leading causes of blindness worldwide.
Sweden’s Affibody and Inmagene, which has wholly owned subsidiaries in San Diego, Shanghai, and Hangzhou, are jointly developing izokibep, a novel bispecific agent, targeting both subunits of IL-17A as well as albumin, to treat multiple autoimmune diseases.